retatrutide trial phase Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released 2 results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Shows 28% Weight Loss

So we're sort of turning those back on

However, as clinicians celebrate these advances, a Read More Why Early Combination Therapy Is Gaining Momentum in Young-Onset Type 2 Diabetes May 19, 2026 Articles, Blood Glucose Control, Devices, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Metformin Therapy Center, SGLT-2 Therapy Center, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,710 views Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults

Are there any side effects from B12

Peptide therapy is not for everyone, which is exactly why every plan starts with a provider review